Christoph Grundner

Title: Christoph Grundner: Innovator in Immunogenic Proteoliposomes

Introduction

Christoph Grundner is a notable inventor based in Oakland, CA (US). He has made significant contributions to the field of immunology through his innovative work on immunogenic proteoliposomes. His research focuses on the development of novel methods and applications that can enhance immune responses.

Latest Patents

Christoph Grundner holds 1 patent for his invention titled "Immunogenic proteoliposomes, and uses thereof." This patent describes an immunogenic proteoliposome that contains a transmembrane protein or oligomeric complexes, including viral envelope glycoproteins, encapsulated within a lipid membrane. The design features an elliptoid or spherical shape, which may also include an attractant such as streptavidin or avidin. The lipid membrane is engineered to bind to this attractant using a moiety like biotin. The immunogenic transmembrane protein is anchored to a ligand within the structure. The patent outlines methods for creating these immunogenic proteoliposomes and discusses their applications, including their use as immunogens to provoke immune reactions and their role in screening assays for antibody libraries, drug screening, and ligand identification.

Career Highlights

Christoph Grundner is currently affiliated with the Dana-Farber Cancer Institute Inc., where he continues to advance his research in immunology. His work has the potential to impact various therapeutic areas, particularly in cancer treatment and vaccine development.

Collaborations

Throughout his career, Christoph has collaborated with esteemed colleagues such as Tajib Mirzabekov and Joseph G Sodroski. These partnerships have fostered a collaborative environment that enhances the research and development of innovative solutions in immunology.

Conclusion

Christoph Grundner's contributions to the field of immunogenic proteoliposomes exemplify the importance of innovation in medical research. His work not only advances scientific understanding but also holds promise for future therapeutic applications.